Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Lefebvre EricOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,800Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Lefebvre EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,900Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Hull HansOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Hull HansOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Ouimette MikeOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Ouimette MikeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cummings Keith LamontOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:110,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cummings Keith LamontOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:55,250Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cheung LilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:52,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cheung LilyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:26,000Price:--
Filings by filing date
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Lefebvre EricOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,800Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Lefebvre EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,900Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Hull HansOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Hull HansOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Ouimette MikeOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Ouimette MikeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cummings Keith LamontOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:110,500Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cummings Keith LamontOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:55,250Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cheung LilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:52,000Price:--
-
Jan 23, 2024 (filed on Jan 24, 2024)Insider Name:Cheung LilyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:26,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 260 Littlefield Avenue, Suite 150 SOUTH SAN FRANCISCO CA 94080 |
Tel: | 1-650-4816770 |
Website: | https://pliantrx.com |
IR: | See website |
Key People | ||
Bernard J. Coulie President, Chief Executive Officer, Director | Keith Cummings Chief Financial Officer | Lily Cheung Chief Human Resource Officer |
Mike Ouimette General Counsel, Corporate Secretary | S. Mishima Gerhart Chief Regulatory Officer | Hans P. Hull Chief Business Officer |
Minnie Kuo Chief Development Officer | Eric Lefebvre Chief Medical Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Pliant Therapeutics Inc revenues decreased 84% to $1.6M. Net loss increased 31% to $161.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 25% to $109.8M (expense), Stock-based Compensation in SGA increase of 91% to $26.5M (expense). |
Employees: | 158 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $314.58M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.58M as of Dec 31, 2023 |
EBITDA (TTM): | -$182.20M as of Dec 31, 2023 |
Net annual income (TTM): | -$161.34M as of Dec 31, 2023 |
Free cash flow (TTM): | -$117.28M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 60,239,176 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |